Car T-Cell Therapy

The Society for Immunotherapy of Cancer published clinical practice guidelines on the management of toxicities related to the use of immune effector cell therapies, including chimeric antigen receptor T cells.

The FDA granted accelerated approval to axicabtagene ciloleucel for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, according to a press release from the agent’s manufacturer.

Patients with relapsed or refractory large B-cell lymphoma who received lisocabtagene maraleucel had similar response rates regardless of the type of center providing the chimeric antigen receptor T-cell therapy, according to study results.

Complete responses to idecabtagene vicleucel appeared consistent regardless of age among patients with relapsed or refractory multiple myeloma, according to study results presented at TCT Meetings Digital Experience.

Chimeric antigen receptor T-cell therapy has been heralded as a transformative addition to the cancer treatment armamentarium.

Younger patients who experienced disease progression after CD19-directed chimeric antigen receptor T-cell therapy had significantly shorter OS than those who did not relapse, according to results presented at TCT Meetings Digital Experience.

Sixty-five percent of patients with relapsed or refractory follicular lymphoma had an initial complete response to a single infusion of tisagenlecleucel, according to phase 2 study results presented at TCT Meetings Digital Experience.

An investigational chimeric antigen receptor T-cell therapy appeared safe and demonstrated antitumor activity among patients with relapsed or refractory B-cell malignancies, according to results presented at TCT Meetings Digital Experience.

Children and young adults with acute lymphoblastic leukemia who received higher doses of tisagenlecleucel achieved significantly longer OS and RFS, according to study results presented at TCT Meetings Digital Experience.

Younger Black patients who received tisagenlecleucel for acute lymphoblastic leukemia had significantly poorer outcomes than those of other races or ethnicities, according to results presented at TCT Meetings Digital Experience.